A new oral cephem antibiotic, BMY-28100 in urinary tract infection

A new oral cephem antibiotic, BMY-28100, was administered in the treatment of 39 UTI patients for the evaluation of its clinical efficacy and safety. The patients treated were 39 adults (1 male and 38 females) including 25 cases of acute simple UTI (pyelonephritis 2, cystitis 23) and 14 of chronic complicated UTI (pyelonephritis 5, cystitis 9). The drug was given at a dose of 500-1000mg a day divided 2 or 3 times for 3-7 days. The clinical efficacy was effective in 23 of 25 cases (92%) in acute simple UTI, and in 10 of 14 cases (71%) in chronic complicated UTI. Bacteriologically, 22 of 24 strains (92%) in acute simple UTI and 13 of 16 strains (81%) in complicated UTI were eradicated. As for side reactions, soft stool with mild gastric discomfort was noted in one case and temporary increase of vaginal fluor in another. Both disappeared soon after discontinuance of the drug. No clinical abnormal values were encountered. We consider BMY-28100 to be a useful and safe oral cephem antibiotic for twice daily administration in the treatment of simple and complicated UTI.